Aducanumab is a human monoclonal antibody that has been studied for the treatment of Alzheimer's disease (AD). It was developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer. The antibody targets aggregated forms of β-amyloid found in the brains of people with Alzheimer’s disease, in the hopes of reducing its buildup. Biogen halted development of the drug in March 2019 after preliminary data from two phase III trials suggested it would not meet the primary endpoint. On 22 October 2019 Biogen announced that it would be re-starting the FDA approval process for aducanumab stating that new analysis of a larger dataset showed that the drug reduced clinical decline in patients with early Alzheimer's disease when given at higher doses. The reanalysis of the data from the discontinued trial concluded that patients receiving a high dose had a 23% reduction in their rate of decline.
Interim results from the second Phase 1 study of the drug wer
[*] Cynthia Fox for Drug Discovery and Development (April 28, 2015). "The Story of Biogen's Alzheimer's Drug, Aducanumab Archived 2015-07-01 at the Wayback Machine".
[*]^ Rebecca Zacks for Xconomy (November 20, 2007). "Biogen Inks $380 Million Deal with Swiss Company".
[*]^ Toyn, Jeremy (2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Rev. Clin. Pharmacol. 8 (3): 267–269. doi:10.1586/17512433.2015.1034690. PMID 25860157.
[*]^ "Biogen Halts Promising Alzheimer's Drug Trials Due to Disappointing Results". Time. Retrieved 2019-03-21.
[*]^ CNN, Jacqueline Howard and Jamie Gumbrecht. "Drugmaker to seek approval for Alzheimer's treatment". CNN. Retrieved 2019-10-23.
[*]^ Herper, Matthew (2019-10-22). "In shocking reversal, Biogen to submit Alzheimer's drug for approval". STAT. Retrieved 2019-10-22.
[*]^ "Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies". Biogen. Retrieved 2019-10-22.
[*]^ Matthew Herper for Forbes. March 20, 2015 Biogen Drug Could Inspire New Hope For Alzheimer's Treatments
[*]^ Jump up to:a b Sevigny J.; Chiao P.; Bussière T.; Weinreb P.H.; Williams L.; Maier M.; Dunstan R.; Salloway S.; Chen T.; Ling Y.; O'Gorman J.; Qian F.; Arastu M.; Li M.; Chollate S.; Brennan M.S.; Quintero-Monzon O.; Scannevin R.H.; Arnold H.M.; Engber T.; Rhodes K.; Ferrero J.; Hang Y.; Mikulskis A.; Grimm J.; Hock C.; Nitsch R.M.; Sandrock A. (1 September 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537(7618): 50–56. doi:10.1038/nature19323. PMID 27582220.
[*]^ Li, Yun (21 March 2019). "Biogen shares plunge nearly 30% after ending trial for Alzheimer's drug Aducanumab". CNBC.
[*]^ "First drug to slow Alzheimer's may be available soon". BBC News. 22 October 2019. Retrieved 22 October 2019.
e reported in March 2015.
A phase 1b study was published in August 2016, based on one year of "monthly intravenous infusions" of aducanumab, with brain scans to measure amyloid plaques. Phase 3 clinical trials were ongoing in September 2016, but were canceled in March 2019 after "an independent group's analysis show[ed] that the trials were unlikely to 'meet their primary endpoint.'"
Despite this, in October 2019 the company announced their intention to seek regulatory approval, following a reanalysis of the data